The research of Dr. Sévigny’s team focusses on the functions of extracellular nucleotides, exerted through the activation of P2 receptors, with an emphasis on the enzymes that regulate their concentrations at the cell surface.  Dr. Sévigny and his team have also identified, cloned and characterized six new genes, including the first member of a new family encoding enzymes called NTPDases.  His team is interested in several biological functions including the regulation of inflammation in response to pathogenic determinants, the migration of immune cells, the functions of leukocytes, the contraction of smooth muscles, and in particular the regulation of inflammation of the intestine with an emphasis on epithelial cells and on a potential treatment for inflammatory bowel disease.

Dr Sévigny’s team uses animal models with KO mice as well as methods of cell biology (murine and human primary cells), pharmacology, biochemistry and immunology.

CHUL
2705, boulevard Laurier
T-1-49
Québec, Québec
Canada G1V 4G2
258 entries « 1 of 26 »

Haas CB, Lovászi M, Pacher P, de Souza PO, Pelletier J, Leite RO, Sévigny J, Németh Z, Braganhol E, Haskó G

Extracellular ectonucleotidases are differentially regulated in murine tissues and human polymorphonuclear leukocytes during sepsis and inflammation.

Journal Article

Purinergic Signal, 2021.

Abstract | Links:

Murtaza A, Afzal S, Zaman G, Saeed A, Pelletier J, Sévigny J, Iqbal J, Hassan A

Divergent synthesis and elaboration of structure activity relationship for quinoline derivatives as highly selective NTPDase inhibitor.

Journal Article

Bioorg Chem, 115 , 2021.

Abstract | Links:

Dias AF, Scholl JN, Moritz CEJ, Kagami LP, das Neves GM, Eifler-Lima VL, Cruz-López O, Conejo-García A, Sévigny J, Battastini AMO, Campos JM, Figueiró F

New insights into cytotoxic mechanisms of bozepinib against glioblastoma.

Journal Article

Eur J Pharm Sci, 162 , 2021.

Abstract | Links:

Schachter J, Alvarez CL, Bazzi Z, Faillace MP, Corradi G, Hattab C, Rinaldi DE, Gonzalez-Lebrero R, Molineris MP, Sevigny J, Ostuni MA, Schwarzbaum PJ

Extracellular ATP hydrolysis in Caco-2 human intestinal cell line.

Journal Article

Biochim Biophys Acta Biomembr, 1863 (10), 2021.

Abstract | Links:

Aziz H, Mahmood A, Zaib S, Saeed A, El-Seedi HR, Pelletier J, Sévigny J, Iqbal J

Synthesis, characterization, alkaline phosphatase inhibition assay and molecular modeling studies of 1-benzylidene-2-(4-tert- butylthiazol-2-yl) hydrazines.

Journal Article

J Biomol Struct Dyn, 39 (16), 2021.

Abstract | Links:

Babou Kammoe RB, Kauffenstein G, Pelletier J, Robaye B, Sevigny J

NTPDase1 Modulates Smooth Muscle Contraction in Mice Bladder by Regulating Nucleotide Receptor Activation Distinctly in Male and Female.

Journal Article

Biomolecules, 11 (2), 2021.

Abstract | Links:

Rodriguez-Martinez A, Trapero C, Vidal A, Piulats JM, Gomez de Aranda I, Sevigny J, Fernandez-Montoli ME, Ponce J, Matias-Guiu X, Martin-Satue M

Characterization of the Endometrial MSC Marker Ectonucleoside Triphosphate Diphosphohydrolase-2 (NTPDase2/CD39L1) in Low- and High-Grade Endometrial Carcinomas: Loss of Stromal Expression in the Invasive Phenotypes.

Journal Article

J Pers Med, 11 (5), 2021.

Abstract | Links:

Lopez V, Schakel L, Schuh HJM, Schmidt MS, Mirza S, Renn C, Pelletier J, Lee SY, Sevigny J, Alban S, Bendas G, Muller CE

Sulfated Polysaccharides from Macroalgae Are Potent Dual Inhibitors of Human ATP-Hydrolyzing Ectonucleotidases NPP1 and CD39.

Journal Article

Mar Drugs, 19 (2), 2021.

Abstract | Links:

Iqbal J, Basharat A, Bano S, Abid SMA, Pelletier J, Sévigny J

Identification and Expression Analysis of CD73 Inhibitors in Cervical Cancer.

Journal Article

Med Chem, 17 (8), 2021.

Abstract | Links:

Rubenich DS, de Souza PO, Omizzollo N, Lenz GS, Sevigny J, Braganhol E

Neutrophils: fast and furious-the nucleotide pathway.

Journal Article

Purinergic Signal, 17 (3), 2021.

Abstract | Links:

258 entries « 1 of 26 »
Signaler des ajouts ou des modifications

Active projects

  • A novel approach to treating inflammatory bowel diseases through the blocking of P2Y6 receptors, from 2018-04-01 to 2023-03-31
  • Centre de recherche en arthrite (ARThrite), from 2020-11-03 to 2026-04-30
  • Novel P2Y6 antagonists as a potential therapy for inflammatory bowel disease, from 2021-07-01 to 2024-06-30
  • Role of NTPDase1 and Extracellular Nucleotides in Smooth Muscle Cell Contraction., from 2016-04-01 to 2022-03-31

Recently finished projects

  • Centre de recherche en arthrite de l'Université Laval, from 2019-01-01 to 2020-01-31
  • Soluble NTPDase8 as a novel biological therapy for inflammatory bowel disease, from 2019-07-01 to 2020-06-30
Data provided by the Université Laval research projects registery